Register for our free email digests:
XenoPort, Inc.
http://www.xenoport.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From XenoPort, Inc.
Appointments: EFPIA, Celgene, AcelRx, PureTech Health, Symbiomix, CRISPR Therapeutics and Achaogen
This latest roundup includes EFPIA's appointment of Nathalie Moll to director general, CEO appointments by YposKesi and Symbiomix Therapeutics, as well as various executive appointments by PureTech Health, Arterial Capital Management and Mitra Biotech.
Orphan Drugs Should Be Rarer, Insurers Urge, Citing Price Increases
FDA can improve drug pricing by limiting the number of orphan designations, AHIP argues; worryingly for industry, the agency appears to be already thinking along similar lines.
BMS Scoops Cormorant In $520M Immuno-Oncology Deal
Bristol-Myers Squibb Co. has bolstered its immuno-oncology ambitions by acquiring IL-8 focused Cormorant Pharmaceuticals AB, the 4-year old Swedish biotech. Cormorant’s shareholders are getting $95M up front with the promise of a further $425M if milestones are achieved.
Deals Shaping The Medical Industry, June 2016
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in May 2016.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Drug Delivery